Alembic Pharma receives USFDA EIR for Oral solid formulation facility (F-1) at Panelav
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-09-28 11:07 GMT | Update On 2024-09-28 11:07 GMT
Vadodara: Alembic Pharma has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (US FDA) for the inspection carried out at the Company's Oral Solid Formulation Facility (F-I) at Panelav.
The inspection conducted from 17th July, 2024 to 26th July, 2024.
Medical Dialogues team had earlier reported that the Company had successfully completed the USFDA inspection for its Oral Solid Formulation Facility (F-I) located at Panelav without any Form 483 observation.
Read also: Alembic Pharma receives USFDA approval for schizophrenia drug Paliperidone Extended Release
Headquartered in India, Alembic Pharmaceuticals Limited is a vertically integrated research and development pharmaceutical company. It is is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA.
Read also: Alembic Pharma names Sudhakar Pandiyan as Head -Technical Operations (Sterile & Oncology)
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.